Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMO3AJS)

Drug Name

DG031 Drug Info

Synonyms

Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Discontinued in Phase 3	[1]

Cross-matching ID

PubChem CID: 123723
CAS Number: CAS 128253-31-6
TTD Drug ID: DMO3AJS

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase activating protein (FLAP)	TTDMBF5	AL5AP_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Arachidonate 5-lipoxygenase activating protein (FLAP)	DTT	ALOX5AP	7.104	8.149	7.984	7.741

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification

12 Disease of the respiratory system

Disease Class

ICD-11: CA23 Asthma

The Studied Tissue

Nasal and bronchial airway

The Studied Disease

Asthma [ICD-11:CA23]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Arachidonate 5-lipoxygenase activating protein (FLAP)	DTT	ALOX5AP	9.89E-01	-0.06	-0.05

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5148).
2	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.